Mymd Pharmaceuticals (NASDAQ:QCLS) Shares Down 7.9% – Here’s What Happened

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) traded down 7.9% on Monday. The company traded as low as $0.5750 and last traded at $0.5801. Approximately 234,458 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 15,505,200 shares. The stock had previously closed at $0.63.

Wall Street Analysts Forecast Growth

QCLS has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a research report on Friday, August 7th. Wall Street Zen raised shares of Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 19th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Mymd Pharmaceuticals Trading Down 1.3%

The business has a fifty day simple moving average of $1.67. The stock has a market cap of $4.42 million, a PE ratio of -0.16 and a beta of 2.32.

Mymd Pharmaceuticals (NASDAQ:QCLS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.79) earnings per share for the quarter.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases, inflammation and age-related conditions. The company has historically pursued treatments designed to regulate the immune system and address biological processes associated with chronic disease and aging.

MyMD’s principal investigational product has been MYMD-1, an orally administered small-molecule therapy intended to modulate immune and inflammatory responses.